Abstract 2182
Background
BRAF V600E mutations are present in 5-10% of metastatic colorectal cancer (mCRC) patients, associated with aggressive biology and limited response to standard chemotherapy, especially in second line and beyond. BRAF V600E mutant CRCs have different patterns of gene expression from the BRAF wild-type, and preclinical evidence suggests that microtubule inhibitors have a potential antitumor effect on xenograft models of BRAF V600E mutant CRC; among them, eribulin has greater growth inhibitory activity than either vinblastine or paclitaxel in vitro. In addition, we have experienced a hint of activity for BRAF V600E mutant CRC patients with tumor shrinkage following eribulin treatment (Masuishi T, et al. Ann Oncol, 2018).
Trial design
BRAVERY study is a multicenter phase II study to evaluate the efficacy and safety of eribulin in patients with BRAF V600E mutant mCRC detected in either tumor tissue (primary analysis cohort) or circulating tumor DNA (ctDNA) assay (liquid biopsy cohort). Key eligibility criteria are refractory or intolerant to at least one regimen (including irinotecan or oxaliplatin) containing fluoropyrimidine, an age of 20 years or older, and ECOG performance status of 0–1. Eribulin is administered intravenously at a dose of 1.4 mg/m2 on Days 1 and 8, repeated every 21 days. Primary endpoint is confirmed objective response rate (ORR) by investigator’s assessment. A sample size of the primary analysis cohort is calculated 27 using two-stage design with ORR of 25% deemed promising and 5% unacceptable (one-sided α, 0.05; β, 0.1). Secondary endpoints include progression-free survival, time to treatment failure, disease control rate, overall survival and adverse events. Furthermore, pretreated tissue and serial blood samples are collected for biomarker analysis; especially focused on gene expression associated with BRAF mutant-like CRC as a predictive marker, BRAF mutant allele frequency in ctDNA as early detection of efficacy, and acquired gene alteration as resistant mechanism to eribulin. At the end of April 2018, four patients have been enrolled in primary analysis cohort since March 2018. Clinical trial information: UMIN000031221 and 000031552.
Clinical trial identification
UMIN000031221 and 000031552. 26/March/2018.
Legal entity responsible for the study
Hiroya Taniguchi.
Funding
Japan Agency for Medical Research and Development.
Editorial Acknowledgement
Disclosure
T. Esaki: Grant and personal fees: Eisai. All other authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract